GO
Loading...

Medicine

More

  • Did Dendreon Do Itself In? Wednesday, 25 Mar 2009 | 12:34 PM ET
    dendreon.jpg

    Oh, the Dendreon investor message boards are on fire! And my inbox has a few sparks. Matthew Herper at Forbes wrote a piece today daring to question the integrity of the all-important data due out sometime next month on DNDN's prostate cancer treatment Provenge.

  • Roll Out The Red Carpet! ASCO Goes Hollywood Tuesday, 24 Mar 2009 | 10:45 AM ET
    asco_new_logo.jpg

    All of my, ahem, complaining and whining, to put it politely, about the American Society of Clinical Oncology may not have fallen on deaf ears after all.

  • Genentech & Abbott CEOs Roar Monday, 23 Mar 2009 | 3:47 PM ET
    Genetech

    Art Levinson and Miles White are "Kings of the Jungle." At least Barron's thinks they are. The weekly investment periodical picked the pair as the only two from biopharma to make its annual list of the "30 Most Respected CEOs."

  • My Tweets And Your Emails Friday, 20 Mar 2009 | 4:44 PM ET

    My first week on Twitter has gone pretty well. Despite some Twitter trouble (or should that be twubble?) with website capacity, I've picked up more than 75 followers already.

  • GlaxoSmithKline's New Ally For Alli Friday, 20 Mar 2009 | 11:28 AM ET
    alli_logo.jpg

    Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.

  • Pfizer: Turning The Bad Economy Into Good PR? Thursday, 19 Mar 2009 | 11:01 AM ET
    Pfizer

    Pfizer announced this morning that it's raising the income levels for uninsured people to qualify for cheaper or free drugs because of the bad economy.

  • NEJM Gets At Heart Of Pfizer's/Pharma's Problems Wednesday, 18 Mar 2009 | 5:15 PM ET

    Scientific and medical journals like to keep their distance from the business side of things. That's why I think it's worth noting that a "Perspective" piece--think of it as kind of a newspaper Op-Ed--in "The New England Journal of Medicine" starts by mentioning Pfizer's stock price and its recent proposed acquisition of Wyeth.

  • Sam Waksal Wants Back In Biotech Tuesday, 17 Mar 2009 | 10:55 AM ET
    Sam Waksal

    Despite my repeated invitations for his first post-jailhouse interview on this blog and through one of his contacts, Sam Waksal didn't respond. Given his Manhattan social scene background it should not, perhaps, come as a surprise that the founder of ImClone Systems decided to have his coming-out party in "New York" magazine.

  • Roche Gets Genentech, But At What Price? Monday, 16 Mar 2009 | 12:56 PM ET

    The overwhelming majority of people who have voted in the “Pharma’s Market” poll about the future of Genentech’s execs and top scientists thinks most of them will eventually bolt.

  • I Can’t Get Off Drugs Monday, 16 Mar 2009 | 11:20 AM ET
    pharma_new3.jpg

    Last week was a busy week, to say the least, on the Pharma beat - So I was looking forward to the weekend and escaping all things drug-related. But as fate would have it, it ended up being bookended by references to pharma in a couple of surprising venues.

  • Dendreon Springs Back To Life Friday, 13 Mar 2009 | 1:52 PM ET

    All of a sudden yesterday and today shares of Dendreon  —my favorite biotech story—shot up on heavy volume.

  • A Lucky Friday The 13th For Merck Friday, 13 Mar 2009 | 10:48 AM ET

    Shares of Dow component Merck rare getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.

  • Attention Genentech Employees: Heeeeere's Franz! Thursday, 12 Mar 2009 | 3:29 PM ET

    Only on a day like today when it's wall-to-wall Madoff coverage would a $47 billion deal, the second $40-billion-plus deal to be done in four days, struggle to get some airtime.

  • Can Pfizer's Breakthrough Help Steve Jobs? Thursday, 12 Mar 2009 | 11:27 AM ET
    Apple CEO Steve Jobs introduces the new iPod Nano in San Francisco, Tuesday, Sept. 9, 2008.

    When a press release crosses the wires or pops into the inbox from a Dow component announcing positive late-stage test results on a cancer drug, you rush to get the headlines on the air as quickly as possible.

  • Don't Let The Sun Go Down On Biotech Wednesday, 11 Mar 2009 | 11:03 AM ET
    Elton John

    The Biotechnology Industry Organization just announced that Sir Elton will be the keynote speaker at the 2009 BIO International Convention in Atlanta, the superstar's American hometown.

  • The Genentech Roller Coaster Tuesday, 10 Mar 2009 | 3:34 PM ET
    genetech_logo_new.jpg

    On my Thomson Reuters screen I have the stock quotes of a few dozen of the biopharma companies I cover. Lately, when I glance over at it, there's been a lot of red. With today's market rally, there's a whole lotta green. And that's why the quote in red for Genentech kind of sticks out like a sore thumb.

  • Merck's Dick Clark: I Give Him A 41 Tuesday, 10 Mar 2009 | 10:56 AM ET
    Richard Clark, Merck CEO

    They may have the same name, but America's oldest teenager Dick Clark and Merck's Chairman and CEO Dick Clark appear to have little else in common. One loves the camera, the other not so much.

  • Are You From Jersey?! Big Pharma's From Jersey! Monday, 9 Mar 2009 | 1:00 PM ET
    New Jersey

    New Jersey, where I live and work, is known as "The World's Medicine Chest" or "The Silicon Valley of Pharma."

  • Roche To Genentech: Deal Or No Deal? Friday, 6 Mar 2009 | 3:06 PM ET
    roche_genentech.jpg

    Yeah, "Deal Or No Deal" has become a bit of a tired cliche, but I think it's totally appropriate in the context of the latest salvo in the Roche-Genentech takeover battle.

  • Merck's Jumpin' Januvia Friday, 6 Mar 2009 | 11:10 AM ET

    Japan and Januvia. No, it's not a country—not even a fictional one—even though it sounds like "Genovia" in "The Princess Diaries." It's a diabetes drug from Merck.